SEASTAR MEDICAL HOLDING CORP (ICU) Stock Price, Forecast & Analysis
NASDAQ:ICU • US81256L3024
ICU Key Statistics, Chart & Performance
The current stock price of ICU is 2.76 USD. In the past month the price increased by 18.2%. In the past year, price decreased by -84.05%.
ICU Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ICU. When comparing the yearly performance of all stocks, ICU is a bad performer in the overall market: 94.3% of all stocks are doing better.
ICU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ICU. ICU scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ICU Financial Highlights
Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -8.4. The EPS increased by 32.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.99% | ||
| ROE | -119.2% | ||
| Debt/Equity | 0 |
ICU Forecast & Estimates
5 analysts have analysed ICU and the average price target is 9.18 USD. This implies a price increase of 232.61% is expected in the next year compared to the current price of 2.76.
For the next year, analysts expect an EPS growth of 17.17% and a revenue growth 601.24% for ICU
ICU Ownership
ICU Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 20.26 | 202.161B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.26 | 180.008B | ||
| SYK | STRYKER CORP | 25.62 | 147.637B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.94 | 112.339B | ||
| IDXX | IDEXX LABORATORIES INC | 44.32 | 52.758B | ||
| BDX | BECTON DICKINSON AND CO | 11.2 | 50.332B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.08 | 49.848B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.78 | 38.246B | ||
| RMD | RESMED INC | 20.87 | 37.448B | ||
| DXCM | DEXCOM INC | 29.08 | 29.01B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ICU
Company Profile
Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
Company Info
SEASTAR MEDICAL HOLDING CORP
3513 Brighton Blvd, Suite 410
Denver COLORADO US
Employees: 19
Phone: 18444278100
SEASTAR MEDICAL HOLDING CORP / ICU FAQ
Can you describe the business of SEASTAR MEDICAL HOLDING CORP?
Seastar Medical Holding Corp. operates as a holding company whose subsidiaries manufacture and supply medical devices. The company is headquartered in Denver, Colorado and currently employs 19 full-time employees. The company went IPO on 2021-01-26. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The company has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
What is the current price of ICU stock?
The current stock price of ICU is 2.76 USD. The price increased by 0.73% in the last trading session.
Does ICU stock pay dividends?
ICU does not pay a dividend.
What is the ChartMill technical and fundamental rating of ICU stock?
ICU has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists ICU stock?
ICU stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of SEASTAR MEDICAL HOLDING CORP (ICU)?
SEASTAR MEDICAL HOLDING CORP (ICU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.4).
What is the market capitalization of ICU stock?
SEASTAR MEDICAL HOLDING CORP (ICU) has a market capitalization of 9.94M USD. This makes ICU a Nano Cap stock.